Copyright
©The Author(s) 2019.
World J Clin Cases. Mar 6, 2019; 7(5): 600-615
Published online Mar 6, 2019. doi: 10.12998/wjcc.v7.i5.600
Published online Mar 6, 2019. doi: 10.12998/wjcc.v7.i5.600
Study | Selection | Comparability | Exposure | Randomization | Masking | Accountability of all patients | Quality (score) |
Randomized controlled trial | |||||||
Sadighi et al[18], 2006 | ** | ** | * | 5 | |||
Roth et al[10], 2007 | ** | * | * | 4 | |||
Gao et al[11], 2010 | ** | ** | * | 5 | |||
Babu et al[9], 2017 | * | * | * | 3 | |||
Retrospective study | |||||||
Abbasi et al[19], 2010 | *** | ** | * | 6 | |||
Kilickap et al[8], 2011 | *** | ** | ** | 7 | |||
Teker et al[12], 2014 | **** | ** | *** | 9 |
- Citation: Li B, Chen L, Luo HL, Yi FM, Wei YP, Zhang WX. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis. World J Clin Cases 2019; 7(5): 600-615
- URL: https://www.wjgnet.com/2307-8960/full/v7/i5/600.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i5.600